Some decisions are hard because the right answer is unclear. Others are hard precisely because the right answer is obvious and expensive. Yi-Kai Lo faced the second kind of decision in the middle of the most important clinical trial his company had ever run, with millions of dollars and years of work riding on the choice.
Yi-Kai founded Aneuvo eight years ago with his PhD advisor, building bio-electronic medicine that uses electrical stimulation instead of drugs to help people with spinal cord injuries regain motor control. Bringing that technology through a clinical trial meant putting the company's credibility, and a great deal of its money, entirely on the line at once.
This story moves through four stages: Build, Break, Breakout, and Breakthrough. Each one shows up in the middle of a trial that Aneuvo could not afford to get wrong.
Build
Aneuvo spent years building toward a single moment, a gold standard clinical trial for a spinal cord injury treatment that had never been attempted before. To reduce regulatory risk, Yi-Kai's team spent eleven months in back-and-forth conversation with the FDA about the study's design, a process he describes almost as a negotiation with an agency that also did not have a template to follow. "We don't know how we don't know," he said of the uncertainty on both sides. Eventually the company decided to launch the study before receiving a formal green light, calculating that further delay cost more than the risk of moving without full sign-off. The FDA cleared the study two weeks later.
The trial itself was enormous by the company's standards, costing seven to eight million dollars and running across fourteen research centers from the East Coast to the West Coast. Getting there had required its own kind of growth. A few years earlier, an early setback, a talented engineer quitting only eight or nine months after Yi-Kai founded the company, had forced him to realize that his engineering training had not taught him how to run a business. He brought in a CEO coach and built a habit of meeting twice a week at five in the morning to work through leadership books together, a discipline that was still running by the time the clinical trial began.
About six months into the trial, complaints started arriving from clinical sites. The external electrodes Aneuvo relied on to deliver stimulation were degrading in quality, and when they failed, the treatment a patient received was not slightly weaker. It was, in Yi-Kai's words, useless. Patients were going through the motions of a treatment that was not actually reaching them.
The recognition was immediate, but the decision it forced was not simple. Aneuvo was running a two-year, seven to eight million dollar trial with a fixed timeline, and the team knew that continuing to enroll patients with defective electrodes meant, as Yi-Kai put it, throwing the money into the water. Stopping meant disrupting fourteen research centers and patients who had already scheduled their participation.
The reflection Yi-Kai describes was not instinctive. It came from deliberately walking through the tradeoff with his team rather than deciding alone. "After debating with our team and doing a lot of evaluation and thinking about the contingency plan," he said, the group worked through what continuing would actually cost against what pausing would actually cost, on a trial where either path carried real financial and scientific risk.
The decision that followed was more precise than simply stopping the trial. Aneuvo halted new patient enrollment for roughly six months while it resolved the electrode issue, but let patients already enrolled continue their treatment rather than pulling them out. The team notified all fourteen clinical investigators of the pause and gave them a specific date for when enrollment would resume, treating transparency with its research partners as part of the decision itself rather than an afterthought.
Aneuvo resumed enrollment on schedule, completed the trial, and went on to secure both a CE mark in Europe and FDA approval in the United States for its flagship device. The clearest evidence of what the technology could do came from a hospital in Germany, where a patient with a complete spinal cord injury was able to use a fork to eat cake by himself within three weeks of starting treatment.
The internal shift traces back further than the electrode crisis itself. The habits Yi-Kai built years earlier, after realizing his engineering background had not prepared him to run a company, were the same habits that let him work through the trial's biggest crisis through structured evaluation rather than gut reaction. The discipline of getting outside input before a costly decision was already built into how Aneuvo operated by the time it mattered most.
It would have been easy for Aneuvo to keep enrolling patients while investigating the electrode problem in parallel, protecting the trial's timeline and hoping the fix arrived before the damage compounded. Yi-Kai's team chose the more expensive, more disruptive option instead, because the alternative meant knowingly delivering a treatment that did not work.
That choice is the harder version of a lesson every growth-stage company eventually faces. Knowing something is wrong is not the same as acting on it immediately, especially when acting is costly and waiting is free in the short term. The founders who protect their companies long term are usually the ones willing to eat the short-term cost the moment they have the evidence, rather than the moment it becomes convenient.
